BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Schuster R, Motola-kalay N, Baranovski BM, Bar L, Tov N, Stein M, Lewis EC, Ayalon M, Sagiv Y. Distinct anti-inflammatory properties of alpha1-antitrypsin and corticosteroids reveal unique underlying mechanisms of action. Cellular Immunology 2020;356:104177. [DOI: 10.1016/j.cellimm.2020.104177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, Stockley RA. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020;55:1902410. [PMID: 32165400 DOI: 10.1183/13993003.02410-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Barrecheguren M, Miravitlles M. Treatment with inhaled α1-antitrypsin: a square peg in a round hole? Eur Respir J 2019;54:1901894. [DOI: 10.1183/13993003.01894-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Greulich T, Albert A, Cassel W, Boeselt T, Peychev E, Klemmer A, Ferreira F, Clarenbach C, Torres-Duran ML, Turner AM, Miravitlles M. Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. Int J Chron Obstruct Pulmon Dis 2022;17:53-64. [PMID: 35023913 DOI: 10.2147/COPD.S346051] [Reference Citation Analysis]
5 Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med 2021;21:99. [PMID: 33757485 DOI: 10.1186/s12890-021-01466-x] [Reference Citation Analysis]
6 Annunziata A, Lanza M, Coppola A, Andreozzi P, Spinelli S, Fiorentino G. Alpha-1 Antitrypsin Deficiency: Home Therapy. Front Pharmacol 2021;12:575402. [PMID: 33935692 DOI: 10.3389/fphar.2021.575402] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Tejwani V, Stoller JK. The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:2040622321995691. [PMID: 34408829 DOI: 10.1177/2040622321995691] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Herth FJF, Sandhaus RA, Turner AM, Sucena M, Welte T, Greulich T. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. Int J Chron Obstruct Pulmon Dis 2021;16:2983-96. [PMID: 34754184 DOI: 10.2147/COPD.S325211] [Reference Citation Analysis]
9 Miravitlles M, Nuñez A, Torres-durán M, Casas-maldonado F, Rodríguez-hermosa JL, López-campos JL, Calle M, Rodríguez E, Esquinas C, Barrecheguren M. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17:346-54. [DOI: 10.1080/15412555.2020.1795824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Nakanishi T, Forgetta V, Handa T, Hirai T, Mooser V, Lathrop GM, Cookson WOCM, Richards JB. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur Respir J 2020;56:2001441. [PMID: 32675199 DOI: 10.1183/13993003.01441-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sandhaus RA, Strange C, Zanichelli A, Skålvoll K, Koczulla AR, Stockley RA. Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:3313-22. [PMID: 33328731 DOI: 10.2147/COPD.S276773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
13 Barrecheguren M, O'Hara K, Wilkens M, Boyd J, Kolda E, Lara B, Chorostowska-Wynimko J, Ferrarotti I, Chlumský J, Clarenbach C, Greulich T, Miravitlles M, Sucena M. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. [PMID: 33447613 DOI: 10.1183/23120541.00523-2020] [Reference Citation Analysis]
14 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
15 Sucena M, Gomes J, Guimarães C, Miravitlles M. Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. Pulmonology 2020;26:181-3. [DOI: 10.1016/j.pulmoe.2020.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Quinn M, Ellis P, Pye A, Turner AM. Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives. Ther Clin Risk Manag 2020;16:1243-55. [PMID: 33364772 DOI: 10.2147/TCRM.S234377] [Reference Citation Analysis]
17 Cazzola M, Stolz D, Rogliani P, Matera MG. α1-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev 2020;29:190073. [PMID: 32051168 DOI: 10.1183/16000617.0073-2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
18 Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]